Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-003 in moderate to severe seasonal allergic rhinitis
NCT07291284Phase 3Active, not recruiting
- Sponsor
- LongBio Pharma
- Start
- Aug 2024
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of LP-003 in seasonal allergic rhinitis (SAR), sponsored by LongBio Pharma. Started Aug 2024; status: active, not recruiting.
02
Drugs
LP-003
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT07291284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07291284.